{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/paronychia-acute/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"118743c0-8ede-55bf-b84a-3f9b8fcebdd8","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 489c230c-d81d-4979-8ad7-58c22b78f4a3 --><h2>Changes</h2><!-- end field 489c230c-d81d-4979-8ad7-58c22b78f4a3 -->","summary":null,"htmlStringContent":"<!-- begin item aed090d0-3031-42a7-97ee-877f8d409f9a --><!-- begin field 945bfb45-e64d-42da-b690-1f055c3e204e --><p><strong>January 2021</strong> — minor update. Contraindications and drug interactions for erythromycin have been updated in line with an MHRA drug safety update. </p><!-- end field 945bfb45-e64d-42da-b690-1f055c3e204e --><!-- end item aed090d0-3031-42a7-97ee-877f8d409f9a -->","topic":{"id":"b2bb7fc0-a6db-5872-b76f-83f50e0814ee","topicId":"6c8ca646-4291-4610-b32e-02c43d2c8af9","topicName":"Paronychia - acute","slug":"paronychia-acute","lastRevised":"Last revised in January 2021","chapters":[{"id":"9d232456-a0db-59c3-81d2-6066b705f267","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e855a6e8-ed6f-50da-8601-bb658a2c2142","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b7baf273-3ab9-5b99-91b1-7ff165d7b93e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"118743c0-8ede-55bf-b84a-3f9b8fcebdd8","slug":"changes","fullItemName":"Changes"},{"id":"4ba6812b-5e78-5829-a1ca-8f8a57fe62b4","slug":"update","fullItemName":"Update"}]},{"id":"d477c411-32be-55fe-a86e-08290f4d2b8e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8c33920b-b3ac-508f-b75a-1eff779e03a1","slug":"goals","fullItemName":"Goals"},{"id":"c4185e18-cda2-5c32-93a0-5c296bd5c060","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f88d0725-e6fd-5377-81c4-23ab93a7caf9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4f840bc1-0fc7-584f-873e-932c373ceada","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1532db75-44de-553a-9f1e-252b405093a2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"36684520-6e5e-55c7-9b20-a4036334ed13","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a51d8911-5c44-5fbe-891f-7a1ce243e2d0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3b0bcedc-02f6-597c-91c1-68ad812ee098","slug":"definition","fullItemName":"Definition"},{"id":"dbf72d8a-9d7c-5237-9ec4-41564c1723a2","slug":"causes","fullItemName":"Causes"},{"id":"27706fc3-d0b2-517c-a4ca-f9c337526f6e","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"693a21f1-8661-5aa0-a4ad-4fd293690c1f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a7b667a2-77ed-58ce-85e1-28053b3cbac6","slug":"complications","fullItemName":"Complications"},{"id":"69b0affa-ba11-50c0-b7eb-4164215fff81","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"402635e2-8b5b-510b-8911-de663be26627","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d2b9d442-db59-5ce2-8001-f79b47a0d07b","slug":"clinical-presentation","fullItemName":"Clinical presentation"},{"id":"5fefa9cc-3cd1-5fe6-97c9-b95e84cf7790","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"d056845a-158d-5904-925f-c1f2590f7c8c","fullItemName":"Management","slug":"management","subChapters":[{"id":"2f065baa-02b7-57a9-a6f9-036079cc78af","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"b8188aa3-5a20-53fc-9ac5-f1500bcb20ee","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a2fead58-dca1-5103-8ad8-61ea6110cd3e","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"0ba4b7a5-9a25-5970-b668-a9c7c4fb38af","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"17d25ace-76d2-5ab6-ac1d-8a1238ea8e09","slug":"erythromycin","fullItemName":"Erythromycin"}]},{"id":"6e2d0756-59aa-5521-b157-730945914705","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f5ecaf87-1d35-5c33-8736-46baa81bda4e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9235cf50-84ce-54e7-b840-58aa133fc328","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"592eaa54-938e-528f-ac4e-1f2d1e7bf7b7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"37214d7d-d933-54be-90ef-dc6fabcc7943","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"599ff9f8-a29d-5b76-9429-6e0788baf48f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"a58d49de-b64c-5e6e-8c5b-5c60f36f832c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2bc165bd-1fb7-56b2-8b43-476ce2b9c4a2","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b7baf273-3ab9-5b99-91b1-7ff165d7b93e","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"252fdf27-9483-58de-8fc1-70781a11b8ac","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field bfa31dcb-e034-498e-9d7d-5fb37639bbb8 --><h3>Previous changes</h3><!-- end field bfa31dcb-e034-498e-9d7d-5fb37639bbb8 -->","summary":null,"htmlStringContent":"<!-- begin item 40b3557a-d36d-4705-b227-2fdec5c11066 --><!-- begin field 64bec083-ecdf-425c-88b0-fe22964e6c5c --><p><strong>January 2017 to May 2017 </strong>— reviewed. Literature searches were conducted in January 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. There have been minor structural changes to the topic. Minor changes have been made including consideration of topical antibiotics and the removal of procedural directions for incision and drainage.</p><p><strong>July 2015 </strong>— minor update. The prescribing information sections on erythromycin and clarithromycin have been clarified.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>July 2011 </strong>— minor update. More exact paracetamol dosing for children has been introduced by the Medicines and Healthcare products Regulatory Agency. Prescriptions have been updated to reflect the revised dosing. Issued in July 2011.</p><p><strong>May 2011 </strong>— minor update. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>November 2010 to March 2011 </strong>— CKS topic revised. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.</p><p><strong>July 2007 </strong>— Oilatum Plus discontinued. Minor change to the text made and prescriptions removed. Issued in August 2007.</p><p><strong>December 2006 to March 2007 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.</p><p><strong>October 2006 </strong>— minor update. Analgesia prescriptions updated because new doses of ibuprofen for children are recommended by the British National Formulary. Issued in October 2006.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>September 2003 </strong>— written. Validated in December 2003 and issued in February 2004.</p><!-- end field 64bec083-ecdf-425c-88b0-fe22964e6c5c --><!-- end item 40b3557a-d36d-4705-b227-2fdec5c11066 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}